Loading...
Loading...
TCON| Name | Value |
|---|---|
| Revenues | 3,045.0K |
| Cost of Revenue | 3.0K |
| Gross Profit | 3,042.0K |
| Operating Expense | 2,635.0K |
| Operating I/L | 407.0K |
| Other Income/Expense | 32.0K |
| Interest Income | 37.0K |
| Pretax | 439.0K |
| Income Tax Expense | -2,363.0K |
| Net Income/Loss | 439.0K |
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of cancer therapeutics in the United States. The company's clinical stage products include envafolimab (KN035) and YH001, both targeted at various cancer indications. Additionally, TRACON Pharmaceuticals has collaboration and license agreements with several organizations for the development of its products. Its revenue is generated through the advancement of its clinical stage products and through collaboration and license agreements with other biopharmaceutical companies and research institutions.
